Stoke Therapeutics, Inc. STOK
27.21 USD -0.50 (-1.80%)
At closeNov 10, 2026, 4:01 PM EST
27.21 0.00 0.00%
After hours · Nov 10, 4:01 PM ET
26.80 Day range 28.44
21.81 52-week range 40.22
- YTD
- -14.27%
- 1 year
- +21.64%
News
benzinga.com Stoke Therapeutics Q3 2026 Earnings Call Transcript Stoke Therapeutics (NASDAQ:STOK) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought…
benzinga.com Stoke Therapeutics Q3 EPS $(1.08) Misses $(0.93) Estimate, Sales $11.255M Beat $8.185M Estimate Stoke Therapeutics (NASDAQ:STOK) reported quarterly losses of $(1.08) per share which missed the analyst consensus estimate of $(0.93) by 16.13 percent. This is a 66.15 percent decrease over losses…
benzinga.com Stoke Therapeutics Presents Data For STK-002 Supporting Disease-Modifying Potential In Autosomal Dominant Optic Atrophy At AAO 2026 Annual Meeting –ADOA is the most common inherited optic nerve disorder and is primarily caused by variants in the OPA1 gene that result in insufficient levels of OPA1 protein, leading to progressive and…
benzinga.com Stoke, Biogen Report Lasting Seizure Reductions In Dravet Syndrome Study Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, and Biogen Inc. (NASDAQ:BIIB) today…
benzinga.com Stoke Therapeutics, Biogen Present Data On Zorevunersen As Treatment For Dravet Syndrome At 16th European Epilepsy Congress Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB) today…
benzinga.com JP Morgan Reinstates Overweight on Stoke Therapeutics, Announces $40 Price Target JP Morgan analyst Jessica Fye reinstates Stoke Therapeutics (NASDAQ:STOK) with a Overweight and announces $40 price target.
benzinga.com Guggenheim Reiterates Buy on Stoke Therapeutics, Maintains $60 Price Target Guggenheim analyst Yatin Suneja reiterates Stoke Therapeutics (NASDAQ:STOK) with a Buy and maintains $60 price target.
benzinga.com These Analysts Revise Their Forecasts On Stoke Therapeutics After Q2 Results Stoke Therapeutics (STOK) reported mixed Q2 results with losses of 93 cents per share and sales of $9.325 million. Analysts have mixed opinions.
benzinga.com Wedbush Maintains Outperform on Stoke Therapeutics, Raises Price Target to $40 Wedbush analyst Laura Chico maintains Stoke Therapeutics (NASDAQ:STOK) with a Outperform and raises the price target from $38 to $40.- benzinga.com Canaccord Genuity Maintains Buy on Stoke Therapeutics, Lowers Price Target to $58 Canaccord Genuity analyst Sumant Kulkarni maintains Stoke Therapeutics (NASDAQ:STOK) with a Buy and lowers the price target from $60 to $58.
- benzinga.com Stoke Therapeutics Files Prospectus For Up To $200M ATM Stock Offering; Replaces Prior Program After Selling 4.7M Shares For $146.4M In Net Proceeds Up to $200,000,000Common StockWe previously entered into a Controlled Equity OfferingSM Sales Agreement, or the Sales Agreement, with Cantor Fitzgerald & Co., or Cantor, relating to shares of our…
- benzinga.com Stoke Therapeutics Q2 EPS $(0.93) Misses $(0.80) Estimate, Sales $9.325M Beat $6.044M Estimate Stoke Therapeutics (NASDAQ:STOK) reported quarterly losses of $(0.93) per share which missed the analyst consensus estimate of $(0.80) by 16.25 percent. This is a 132.5 percent decrease over losses…
benzinga.com Goldman Sachs Initiates Coverage On Stoke Therapeutics with Buy Rating, Announces Price Target of $44 Goldman Sachs analyst Kevin Strang initiates coverage on Stoke Therapeutics (NASDAQ:STOK) with a Buy rating and announces Price Target of $44.
benzinga.com Stoke Therapeutics Completes Enrollment Of 162 Patients Into Phase 3 EMPEROR Study Of Zorevunersen; Co Plans To Initiate Rolling NDA Submission To FDA In Q1 Of 2027 —Company plans to initiate a rolling U.S. NDA submission to the FDA in the first quarter of 2027——Phase 3 data readout anticipated in the third quarter of 2027 to complete the rolling U.S. NDA…- benzinga.com BTIG Reiterates Buy on Stoke Therapeutics, Maintains $39 Price Target BTIG analyst Thomas Shrader reiterates Stoke Therapeutics (NASDAQ:STOK) with a Buy and maintains $39 price target.
- benzinga.com Stoke Therapeutics Q1 EPS $(0.79) Beats $(0.84) Estimate, Sales $6.229M Beat $5.880M Estimate. Stoke Therapeutics (NASDAQ:STOK) reported quarterly losses of $(0.79) per share which beat the analyst consensus estimate of $(0.84) by 5.95 percent. This is a 141.58 percent decrease over earnings…
benzinga.com Semtech To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Tuesday Wall Street analysts changed outlook on top names: Morgan Stanley raised Lemonade's PT to $85, Mizuho cut Canadian Solar's PT to $19, Piper Sandler raised Tandem Diabetes' PT to $33, Stifel increased…
benzinga.com Exelixis, Citigroup And Other Big Stocks Moving Lower In Monday's Pre-Market Session 
benzinga.com Why Bark Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket 
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session - benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
benzinga.com Earnings Scheduled For November 4, 2025 - benzinga.com Earnings Scheduled For August 12, 2025
- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
benzinga.com D.R. Horton, IQVIA Holdings, Northrop Grumman And Other Big Stocks Moving Higher On Tuesday 
benzinga.com This Verint Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - benzinga.com Why Westport Fuel Systems Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session Shares of Westport Fuel Systems Inc. (NASDAQ: WPRT) fell sharply during Tuesday’s session after posting a wider-than-expected fourth-quarter loss. Westport Fuel Systems posted a quarter loss of 81…
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday On Wednesday, 311 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday On Tuesday, 647 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday During Thursday's session, 406 companies made new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday On Tuesday, 386 stocks made new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday During the session on Thursday, 461 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday On Wednesday, 179 companies reached new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Monday During Monday's session, 201 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 149 companies reached new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday Wednesday saw 59 companies set new 52-week lows.
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
- benzinga.com Why Alaska Air Group Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session Gainers Aurora Acquisition Corp. (NASDAQ: AURC) shares jumped 192% to $30.54.
benzinga.com Stocks That Hit 52-Week Lows On Tuesday On Tuesday, 56 companies set new 52-week lows.- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- benzinga.com Why Ryanair Holdings Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Monday's Mid-Day Session Gainers Tupperware Brands Corporation (NYSE: TUP) shares jumped 59% to $1.43 on above-average volume amid retail investor interest.
- benzinga.com Scholastic, Matson, Digital World Acquisition And Other Big Stocks Moving Higher On Friday U.S. stocks traded higher, with the Dow Jones gaining around 90 points on Friday. Here are some big stocks recording gains in today’s session.
- benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 72 companies hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday During Tuesday's trading, 160 companies set new 52-week lows.
- benzinga.com Why Karuna Therapeutics Jumped Around 72%; Here Are 96 Biggest Movers From Yesterday Gainers Helbiz, Inc. (NASDAQ: HLBZ) jumped 114.6% to close at $1.61 on Monday after climbing over 27% on Friday.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday On Tuesday, 951 companies hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Monday During Monday's trading, 1214 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday On Thursday, 94 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday On Wednesday, 215 companies set new 52-week lows.